Hereditary Breast and Ovarian Cancer

Pathogenic BRCA1 and BRCA2 variants drive most hereditary breast and ovarian cancer. Referral follows early-onset or triple-negative breast cancer, ovarian cancer at any age, male breast cancer, and multi-generation family history.

Quick approach

  1. Confirm the phenotype: record age at diagnosis, receptor status, histology, laterality and any male breast cancer.
  2. Map a three-generation pedigree covering breast, ovarian, prostate, pancreatic and male breast primaries.
  3. Check testing eligibility against current NCCN or local thresholds before ordering a multi-gene panel.
  4. Classify every variant with ACMG and AMP criteria, and never act on a variant of uncertain significance.
  5. Close the loop: route a positive result to surveillance, risk-reducing options and cascade testing of relatives.

Red flags & when to escalate

Breast cancer before age 45 Triple-negative breast cancer before age 60 Ovarian, tubal or peritoneal carcinoma at any age Male breast cancer at any age Two or more close relatives with breast or ovarian cancer

Guidelines, books & articles

Guideline

NCCN Guidelines: Genetic and Familial High-Risk Assessment — Breast, Ovarian and Pancreatic

National Comprehensive Cancer Network · 2024

The working standard for testing criteria, surveillance schedules and risk-reducing surgery thresholds in hereditary breast, ovarian and pancreatic cancer.

Open source

No sources are linked to this topic yet. Browse the full guidelines and literature list.

Medication doses

No medication doses are linked to this topic yet. See the full dose reference.